Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

被引：90

作者：

Wasilewska, Agnieszka ^{[1
]}

Winiarska, Marta ^{[1
]}

Olszewska, Malgorzata ^{[1
]}

Rudnicka, Lidia ^{[1
]}

机构：

[1] Med Univ Warsaw, Dept Dermatol, 92a Koszykowa St, PL-02008 Warsaw, Poland

来源：

POSTEPY DERMATOLOGII I ALERGOLOGII | 2016年 / 33卷 / 04期

关键词：

alopecia areata; fynomer; lichen planus; pemphigoid; pemphigus; SEVERE PLAQUE PSORIASIS; MONOCLONAL-ANTIBODY; PHASE-II; CLINICAL-RESPONSE; DOUBLE-BLIND; TH17; CELLS; MODERATE; BRODALUMAB; IL-17; SECUKINUMAB;

D O I：

10.5114/ada.2016.61599

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).

引用

页码：247 / 252

页数：6

共 41 条

[1] The Role of Interleukin-17A in Psoriatic Disease [J].

Adami, Silvano ;

Cavani, Andrea ;

Rossi, Francesco ;

Girolomoni, Giampiero .

BIODRUGS, 2014, 28 (06) :487-497

[2] Quality of life in psoriasis patients [J].

Augustin, Matthias ;

Radtke, Marc Alexander .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) :559-568

[3] Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis [J].

Batista, D. I. S. ;

Perez, L. ;

Orfali, R. L. ;

Zaniboni, M. C. ;

Samorano, L. P. ;

Pereira, N. V. ;

Sotto, M. N. ;

Ishizaki, A. S. ;

Oliveira, L. M. S. ;

Sato, M. N. ;

Aoki, V. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) :1091-1095

[4] Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].

Blauvelt, A. ;

Prinz, J. C. ;

Gottlieb, A. B. ;

Kingo, K. ;

Sofen, H. ;

Ruer-Mulard, M. ;

Singh, V. ;

Pathan, R. ;

Papavassilis, C. ;

Cooper, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493

[5] Emerging Role of IL-17 in Atherosclerosis [J].

Chen, Shuang ;

Crother, Timothy R. ;

Arditi, Moshe .

JOURNAL OF INNATE IMMUNITY, 2010, 2 (04) :325-333

[6] IL-17 targeted therapies for psoriasis [J].

Chiricozzi, Andrea ;

Krueger, James G. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) :993-1005

[7] Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis [J].

Coimbra, Susana ;

Figueiredo, Americo ;

Santos-Silva, Alice .

CORE EVIDENCE, 2014, 9 :89-97

[8] Recent advances in the IL-17 cytokine family [J].

Gaffen, Sarah L. .

CURRENT OPINION IN IMMUNOLOGY, 2011, 23 (05) :613-619

[9] Structure and signalling in the IL-17 receptor family [J].

Gaffen, Sarah L. .

NATURE REVIEWS IMMUNOLOGY, 2009, 9 (08) :556-567

[10] Effect of Th17 and Treg Axis Disorder on Outcomes of Pulmonary Arterial Hypertension in Connective Tissue Diseases [J].

Gaowa, Saren ;

Zhou, Wenyong ;

Yu, Lilei ;

Zhou, Xiaohui ;

Liao, Kai ;

Yang, Kang ;

Lu, Zhibin ;

Jiang, Hong ;

Chen, Xiaofeng .

MEDIATORS OF INFLAMMATION, 2014, 2014

← 1 2 3 4 5 →